Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
177Lu-LNC1004
i
Other names:
177Lu-LNC1004, 177Lu-EB-FAPI
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Dongcheng Pharma
Drug class:
Ionizing radiation emitter, FAP inhibitor
Related drugs:
‹
177Lu-satetraxetan-lilotomab (4)
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
lutetium Lu 177 dotatate (2)
PNT2002 (2)
radium Ra-223 dichloride (2)
CLR 131 (2)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
AAA603 (0)
iodine I 131 tositumomab (0)
CAM-H2 (0)
samarium-153 DOTMP (0)
Debio 0228 (0)
EBTATE (0)
FF21101 (0)
ITM-31 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
Re (0)
177Lu-DOTA-EB-FAPI (0)
BI 765179 (0)
MP0310 (0)
MP0317 (0)
NG-641 (0)
RG7827 (0)
SHR-7367 (0)
[177Lu]FAPI-46 (0)
RG7461 (0)
BXCL701 (0)
177Lu-satetraxetan-lilotomab (4)
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
lutetium Lu 177 dotatate (2)
PNT2002 (2)
radium Ra-223 dichloride (2)
CLR 131 (2)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
AAA603 (0)
iodine I 131 tositumomab (0)
CAM-H2 (0)
samarium-153 DOTMP (0)
Debio 0228 (0)
EBTATE (0)
FF21101 (0)
ITM-31 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
Radspherin (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
Re (0)
177Lu-DOTA-EB-FAPI (0)
BI 765179 (0)
MP0310 (0)
MP0317 (0)
NG-641 (0)
RG7827 (0)
SHR-7367 (0)
[177Lu]FAPI-46 (0)
RG7461 (0)
BXCL701 (0)
›
Associations
News
Trials
Filter by
Latest
7ms
CISPD-5: A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors (clinicaltrials.gov)
P1, N=29, Recruiting, Zhejiang University
7 months ago
New P1 trial • Metastases
|
177Lu-LNC1004
1year
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection (clinicaltrials.gov)
P1, N=24, Not yet recruiting, Yantai LNC Biotechnology Singapore PTE. LTD.
1 year ago
New P1 trial
|
FAP (Fibroblast activation protein, alpha)
|
177Lu-LNC1004
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login